151 likes | 350 Views
CardioQ-ODM oesophageal doppler monitor. Implementing NICE guidance. March 2011. NICE medical technology guidance 3. What this presentation covers. Background Guidance Costs and savings Discussion Accessing the guidance and implementation tools.
E N D
CardioQ-ODM oesophageal doppler monitor Implementing NICE guidance March 2011 NICE medical technology guidance 3
What this presentation covers • Background • Guidance • Costs and savings • Discussion • Accessing the guidance and implementation tools
Background: medical technologies guidance • NICE medical technology guidance addresses specific technologies notified to NICE by manufacturers. • If the case for adopting the technology is supported, then the technology has been found to offer advantages to patients and the NHS. • The specific recommendations on individual technologies are not intended to limit use of other relevant technologies that may offer similar advantages.
Background: current clinical practice • To ensure adequate organ perfusion during surgery it is essential to optimise intravascular volume and cardiac output • Methods for measuring this include: • conventional clinical assessment of heart rate and blood pressure • central venous catheter monitoring • pulse contour analysis • dye dilution • measurement of thoracic electrical impedance • transoesophageal echocardiography • pulmonary artery catheters
Background: CardioQ-ODM • An oesophageal doppler monitor that assesses cardiac output and intravascular fluid status • A single-use probe is placed in the oesophagus • Ultrasound signal is reflected by red blood cells in the aorta; stroke volume and cardiac output can be measured from the reflected signal • Fluid management during surgery is guided by using the CardioQ-ODM to monitor changes in stroke volume
Guidance (1) • Compared with conventional clinical assessment (with or without invasive cardiovascular monitoring) the CardioQ-OMD is associated with reduced: • postoperative complications • use of central venous catheters • in-hospital stay • The case for adopting it in the NHS is supported by the evidence Image reproduced with kind permission of Deltex Medical Group plc.
Guidance (2) • Consider the CardioQ-ODM for patients having major or high-risk surgery or other surgical patients in whom invasive cardiovascular monitoring would be considered Image reproduced with kind permission of Deltex Medical Group plc.
Costs and savings: the equipment • If the CardioQ-ODM is used in 50% of eligible patients, the initial outlay for the monitors could be repaid by savings made after 10 days
Discussion • Clinicians • How can we prepare a case for the organisation to invest in this technology? • How can we encourage our colleagues to use this technology? • Management • What needs to be done to facilitate the purchase of the CardioQ-ODM device in our organisation? • What can we do to facilitate implementation of the device within our organisation?
Accessing the guidance and implementation tools online • Guidance • Costing tools • Podcast • available from: www.nice.org.uk/MTG3 Image reproduced with kind permission of Deltex Medical Group plc.
What do you think? • Did the implementation tool you accessed today meet your requirements, and will it help you to put the NICE guidance into practice? • We value your opinion and are looking for ways to improve our tools. Please complete a short evaluation form. • If you have problems accessing or using this tool, please email implementation@nice.org.uk To open the links in this slide set right click over the link and choose ‘open link’